32. Prioritize the pediatric TB diagnostic space to ensure there are improved tools for pediatric TB infection and disease detection to reach and maintain targets.

​

33. Develop quality-assured, affordable, less invasive alternative specimen processing methods or products (not based only on sputum) that can be used for the pediatric population, such as urine, stool or saliva.

​

34. Ensure diagnostic studies include children and alternative (non-sputum-based) sample types.

​

35. Expedite development of point-of-care biomarker-based tests for infants and children.

​

36. Consider moving from separate instrument, consumable, and service procurement towards more consolidated, all-inclusive pricing models, for both laboratory-based and point-of-care technologies.

​

37. Provide service level agreements that clearly spell out key performance indicators for all technology types and their offered service plans, plus a mitigation plan when the threshold is exceeded.

​

60. Prioritize attainment of WHO recommendation of the FluoroType MTBDR assay.

​

61. Prioritize obtaining waivers for GenoType and FluoroType assay technologies for countries under US embargo.

​

62. Offer access pricing and prospective reductions based on global volume thresholds; publish the volumes procured quarterly.

​

63. Consider introduction of a diagnostic connectivity solution that is API-capable for automatic reporting of line probe assay test results to users and other information management systems.

 

​